Ost-müük AstraZeneca PLC - GBP - AZNl CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.32 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.022491% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.000573% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | GBP | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United Kingdom of Great Britain and Northern Ireland | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
AstraZeneca PLC ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Eelmine sulgemine* | 111.36 |
Avatud* | 111.02 |
Aastane muutus* | 10.61% |
Päeva ulatus* | 111.02 - 112.16 |
52 nädala ulatus | 93.99-128.29 |
Keskmine maht (10 päeva) | 1.50M |
Keskmine maht (3 kuud) | 42.59M |
Turukapitalisatsioon | 172.05B |
P/E suhtarv | 65.22 |
Ringluses olevad aktsiad | 1.55B |
Tulu | 35.82B |
EPS | 1.70 |
Dividendid (% kasumist) | 2.14222 |
Beeta | 0.27 |
Järgmine tuluaruande kuupäev | Apr 27, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Mar 30, 2023 | 111.34 | -0.04 | -0.04% | 111.38 | 112.22 | 110.80 |
Mar 29, 2023 | 111.36 | 1.02 | 0.92% | 110.34 | 111.90 | 110.34 |
Mar 28, 2023 | 111.38 | -0.02 | -0.02% | 111.40 | 112.84 | 111.28 |
Mar 27, 2023 | 112.64 | 1.96 | 1.77% | 110.68 | 112.88 | 110.68 |
Mar 24, 2023 | 110.48 | 1.12 | 1.02% | 109.36 | 110.82 | 109.36 |
Mar 23, 2023 | 109.85 | 1.58 | 1.46% | 108.27 | 110.08 | 108.27 |
Mar 22, 2023 | 109.49 | 1.54 | 1.43% | 107.95 | 109.71 | 107.51 |
Mar 21, 2023 | 108.79 | 0.06 | 0.06% | 108.73 | 109.19 | 107.49 |
Mar 20, 2023 | 107.81 | 1.30 | 1.22% | 106.51 | 108.01 | 106.41 |
Mar 17, 2023 | 107.67 | 0.06 | 0.06% | 107.61 | 109.11 | 107.29 |
Mar 16, 2023 | 107.87 | 2.10 | 1.99% | 105.77 | 108.15 | 105.77 |
Mar 15, 2023 | 106.29 | -0.60 | -0.56% | 106.89 | 107.85 | 106.19 |
Mar 14, 2023 | 106.47 | 0.22 | 0.21% | 106.25 | 107.17 | 105.51 |
Mar 13, 2023 | 106.69 | -0.18 | -0.17% | 106.87 | 108.47 | 105.43 |
Mar 10, 2023 | 106.63 | -0.74 | -0.69% | 107.37 | 108.49 | 105.77 |
Mar 9, 2023 | 108.53 | 0.78 | 0.72% | 107.75 | 109.33 | 107.69 |
Mar 8, 2023 | 107.95 | -0.36 | -0.33% | 108.31 | 108.89 | 107.75 |
Mar 7, 2023 | 108.29 | 2.40 | 2.27% | 105.89 | 108.93 | 105.89 |
Mar 6, 2023 | 107.33 | -0.06 | -0.06% | 107.39 | 108.05 | 106.99 |
Mar 3, 2023 | 107.93 | 0.06 | 0.06% | 107.87 | 108.73 | 107.71 |
AstraZeneca PLC - GBP Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
Friday, March 31, 2023 | ||
Kellaaeg (UTC) (UTC) 10:59 | Riik GB
| Sündmus AstraZeneca PLC at Carnegie Roadshow - Helsinki AstraZeneca PLC at Carnegie Roadshow - HelsinkiForecast -Previous - |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 44351 | 37417 | 26617 | 24384 | 22090 |
Tulu | 44351 | 37417 | 26617 | 24384 | 22090 |
Kulud, Kokku | 8649 | 9542 | 5270 | 4824 | 4246 |
Brutokasum | 35702 | 27875 | 21347 | 19560 | 17844 |
Kogu tegevuskulu | 40594 | 36361 | 21455 | 21460 | 18703 |
Müük/Üldine/admin kulud, kokku | 13512 | 11519 | 9338 | 8964 | 8479 |
Uuringud ja arendus | 9612 | 8519 | 6094 | 5320 | 5266 |
Depreciation / Amortization | 4094 | 3044 | 1897 | 1812 | 1945 |
Ootamatud kulutused (tulu) | 4820 | 3846 | -763 | 863 | -953 |
Other Operating Expenses, Total | -93 | -109 | -381 | -323 | -280 |
Tulud majandustegevusest | 3757 | 1056 | 5162 | 2924 | 3387 |
Intressitulud (kulu), muud tulud, neto | -815 | -819 | -716 | -766 | -775 |
Muud, neto | -441 | -502 | -530 | -610 | -619 |
Netotulu enne makse | 2501 | -265 | 3916 | 1548 | 1993 |
Netotulu pärast makse | 3293 | 115 | 3144 | 1227 | 2050 |
Vähemuse intress | -5 | -3 | 52 | 108 | 105 |
Netotulu enne erikulusid | 3288 | 112 | 3196 | 1335 | 2155 |
Netotulu | 3288 | 112 | 3196 | 1335 | 2155 |
Arvestatav tulu, v a erikulud | 3288 | 112 | 3196 | 1335 | 2155 |
Arvestatav tulu, koos erikuludega | 3288 | 112 | 3196 | 1335 | 2155 |
Jaotuse korrigeerimine | 0 | 0 | |||
Jaotamisele kuuluv netotulu | 3288 | 112 | 3196 | 1335 | 2155 |
Keskmine jaotamisele kuuluv aktsia kohta | 1560 | 1427 | 1313 | 1301 | 1267 |
Jaotatav EPS, v a erakorralised kulud | 2.10769 | 0.07849 | 2.43412 | 1.02613 | 1.70087 |
Dividends per Share - Common Stock Primary Issue | 2.89361 | 2.84245 | 2.83031 | 2.89446 | 2.74532 |
Jaotamisele kuuluv normaal-EPS | 3.8859 | 2.22705 | 1.88804 | 1.48501 | 0.85399 |
Intressikulu (tulu) - neto majandustegevusest | 0 | 0 | |||
Erakorralised kulud kokku |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Kogutulu | 11207 | 10982 | 10771 | 11390 | 12011 |
Tulu | 11207 | 10982 | 10771 | 11390 | 12011 |
Kulud, Kokku | 2512 | 2118 | 1904 | 2279 | 3069 |
Brutokasum | 8695 | 8864 | 8867 | 9111 | 8942 |
Kogu tegevuskulu | 10113 | 9737 | 10232 | 10512 | 12303 |
Müük/Üldine/admin kulud, kokku | 3598 | 3353 | 3633 | 3057 | 4082 |
Uuringud ja arendus | 2525 | 2357 | 2431 | 2186 | 2927 |
Depreciation / Amortization | 1034 | 979 | 983 | 1098 | 1066 |
Ootamatud kulutused (tulu) | 324 | 1002 | 1298 | 1953 | 1007 |
Other Operating Expenses, Total | 120 | -72 | -17 | -61 | 152 |
Tulud majandustegevusest | 1094 | 1245 | 539 | 878 | -292 |
Intressitulud (kulu), muud tulud, neto | -316 | -323 | -292 | -325 | -344 |
Netotulu enne makse | 778 | 922 | 247 | 553 | -636 |
Netotulu pärast makse | 902 | 1642 | 360 | 388 | -346 |
Vähemuse intress | -1 | -2 | 0 | -2 | -1 |
Netotulu enne erikulusid | 901 | 1640 | 360 | 386 | -347 |
Netotulu | 901 | 1640 | 360 | 386 | -347 |
Arvestatav tulu, v a erikulud | 901 | 1640 | 360 | 386 | -347 |
Arvestatav tulu, koos erikuludega | 901 | 1640 | 360 | 386 | -347 |
Jaotuse korrigeerimine | |||||
Jaotamisele kuuluv netotulu | 901 | 1640 | 360 | 386 | -347 |
Keskmine jaotamisele kuuluv aktsia kohta | 1560 | 1559 | 1560 | 1561 | 1550 |
Jaotatav EPS, v a erakorralised kulud | 0.57756 | 1.05196 | 0.23077 | 0.24728 | -0.22387 |
Dividends per Share - Common Stock Primary Issue | 1.9694 | 0 | 0.93017 | 0 | 1.96577 |
Jaotamisele kuuluv normaal-EPS | 0.81923 | 0.99743 | 0.80833 | 1.24792 | 1.00645 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Käibevarad kokku | 26244 | 19544 | 15563 | 15591 | 13150 |
Raha ja lühiajalised investeeringud | 6398 | 7992 | 6218 | 5680 | 4554 |
Cash | 1461 | 1182 | 755 | 893 | 784 |
Raha ja ekvivalendid | 4868 | 6650 | 4614 | 3938 | 2540 |
Lühiajalised investeeringud | 69 | 160 | 849 | 849 | 1230 |
Laekumata arved, neto | 8795 | 5651 | 5181 | 4345 | 4275 |
Accounts Receivable - Trade, Net | 6324 | 3956 | 3813 | 2995 | 2802 |
Total Inventory | 8983 | 4024 | 3193 | 2890 | 3035 |
Prepaid Expenses | 1512 | 1735 | 865 | 1436 | 1258 |
Other Current Assets, Total | 556 | 142 | 106 | 1240 | 28 |
Total Assets | 105363 | 66729 | 61377 | 60651 | 63354 |
Property/Plant/Equipment, Total - Net | 10171 | 8917 | 8335 | 7421 | 7615 |
Property/Plant/Equipment, Total - Gross | 18495 | 17110 | 15852 | 14639 | 14639 |
Accumulated Depreciation, Total | -8324 | -8193 | -7517 | -7218 | -7024 |
Goodwill, Net | 19997 | 11845 | 11668 | 11707 | 11825 |
Intangibles, Net | 42387 | 20947 | 20833 | 21959 | 26188 |
Long Term Investments | 1237 | 1147 | 1459 | 922 | 1036 |
Note Receivable - Long Term | 504 | 325 | 348 | 515 | 847 |
Other Long Term Assets, Total | 4823 | 4004 | 3171 | 2536 | 2693 |
Total Current Liabilities | 22594 | 20307 | 18117 | 16292 | 16383 |
Accounts Payable | 2824 | 2350 | 1774 | 1720 | 3611 |
Accrued Expenses | 8079 | 4994 | 5085 | 5148 | 3794 |
Notes Payable/Short Term Debt | 294 | 370 | 154 | 160 | 152 |
Current Port. of LT Debt/Capital Leases | 1599 | 2016 | 1856 | 1594 | 2095 |
Other Current Liabilities, Total | 9798 | 10577 | 9248 | 7670 | 6731 |
Total Liabilities | 66095 | 51107 | 48250 | 48183 | 48394 |
Total Long Term Debt | 28888 | 17994 | 16217 | 17359 | 15560 |
Long Term Debt | 28134 | 17505 | 15730 | 17359 | 15560 |
Capital Lease Obligations | 754 | 489 | 487 | 0 | 0 |
Deferred Income Tax | 6206 | 2918 | 2490 | 3286 | 3995 |
Minority Interest | 19 | 16 | 1469 | 1576 | 1682 |
Other Liabilities, Total | 8388 | 9872 | 9957 | 9670 | 10774 |
Total Equity | 39268 | 15622 | 13127 | 12468 | 14960 |
Common Stock | 387 | 328 | 328 | 317 | 317 |
Additional Paid-In Capital | 35126 | 7971 | 7941 | 4427 | 4393 |
Retained Earnings (Accumulated Deficit) | 3755 | 7323 | 4858 | 7724 | 10250 |
Total Liabilities & Shareholders’ Equity | 105363 | 66729 | 61377 | 60651 | 63354 |
Total Common Shares Outstanding | 1549.4 | 1312.67 | 1312.14 | 1267.04 | 1266.22 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 22647 | 26244 | 26691 | 27274 | 18735 |
Raha ja lühiajalised investeeringud | 5823 | 6398 | 7149 | 15629 | 7765 |
Raha ja ekvivalendid | 5762 | 6329 | 7067 | 15567 | 7636 |
Lühiajalised investeeringud | 61 | 69 | 82 | 62 | 129 |
Laekumata arved, neto | 9050 | 10307 | 8854 | 6842 | 6628 |
Accounts Receivable - Trade, Net | 8683 | 9644 | 8258 | 6356 | 6281 |
Total Inventory | 7624 | 8983 | 10528 | 4762 | 4278 |
Other Current Assets, Total | 150 | 556 | 160 | 41 | 64 |
Total Assets | 100273 | 105363 | 107221 | 73641 | 64926 |
Property/Plant/Equipment, Total - Net | 10015 | 10171 | 10162 | 9031 | 8849 |
Goodwill, Net | 19963 | 19997 | 20081 | 11798 | 11765 |
Intangibles, Net | 41265 | 42387 | 44104 | 20006 | 20347 |
Long Term Investments | 1237 | 1237 | 1585 | 1120 | 1060 |
Note Receivable - Long Term | 864 | 895 | 811 | 565 | 549 |
Other Long Term Assets, Total | 4282 | 4432 | 3787 | 3847 | 3621 |
Total Current Liabilities | 22740 | 22594 | 23649 | 22222 | 21513 |
Payable/Accrued | 17864 | 18938 | 18663 | 17729 | 17370 |
Notes Payable/Short Term Debt | 724 | 294 | 500 | 392 | 407 |
Current Port. of LT Debt/Capital Leases | 1570 | 1599 | 2473 | 2502 | 1851 |
Other Current Liabilities, Total | 2582 | 1763 | 2013 | 1599 | 1885 |
Total Liabilities | 63933 | 66095 | 67477 | 57965 | 50496 |
Total Long Term Debt | 28805 | 28888 | 28939 | 24601 | 17874 |
Long Term Debt | 28081 | 28134 | 28206 | 24109 | 17410 |
Capital Lease Obligations | 724 | 754 | 733 | 492 | 464 |
Deferred Income Tax | 5626 | 6206 | 6400 | 2927 | 2823 |
Minority Interest | 19 | 19 | 168 | 17 | 16 |
Other Liabilities, Total | 6743 | 8388 | 8321 | 8198 | 8270 |
Total Equity | 36340 | 39268 | 39744 | 15676 | 14430 |
Common Stock | 387 | 387 | 387 | 328 | 328 |
Additional Paid-In Capital | 35131 | 35126 | 35118 | 7980 | 7976 |
Retained Earnings (Accumulated Deficit) | 822 | 3755 | 4239 | 7368 | 6126 |
Total Liabilities & Shareholders’ Equity | 100273 | 105363 | 107221 | 73641 | 64926 |
Total Common Shares Outstanding | 1549.45 | 1549.4 | 1549.14 | 1312.79 | 1312.74 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -265 | 3916 | 1548 | 1993 | 2227 |
Raha majandustegevusest | 5963 | 4799 | 2969 | 2618 | 3578 |
Raha majandustegevusest | 6530 | 3149 | 3762 | 3753 | 3036 |
Mittelikviidsed varad | 141 | -332 | -103 | -1276 | -483 |
Cash Taxes Paid | 1743 | 1562 | 1118 | 537 | 454 |
Makstud intressid | 721 | 733 | 774 | 676 | 698 |
Muutused tööjõus | -443 | -1934 | -2238 | -1852 | -1202 |
Tulu investeeringutelt | -11058 | -285 | -657 | 963 | -2328 |
Kapitalikulutused | -2200 | -2606 | -2460 | -1371 | -1620 |
Muud rahavood investeeringutelt, kokku | -8858 | 2321 | 1803 | 2334 | -708 |
Rahavood investeeringutelt | 3649 | -2203 | -1765 | -2044 | -2936 |
Rahavoogudesse investeerimine | -178 | -101 | 4 | -67 | -20 |
Total Cash Dividends Paid | -3856 | -3572 | -3592 | -3484 | -3519 |
Aktsiate emiteerimine (tagasiost), neto | 29 | 30 | 3525 | 34 | 43 |
Laenu väljastamine (kustutamine), neto | 7654 | 1440 | -1702 | 1473 | 560 |
Muutused valuutakursside kõikumisest | -62 | 12 | 5 | -38 | -66 |
Rahaline kogumuutus | -1508 | 2323 | 552 | 1499 | -1752 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 553 | -265 | 371 | 2372 | 1608 |
Cash From Operating Activities | 3232 | 5963 | 4545 | 2826 | 1934 |
Cash From Operating Activities | 1309 | 6530 | 4338 | 1550 | 797 |
Non-Cash Items | -12 | 141 | -507 | -761 | -1162 |
Cash Taxes Paid | 228 | 1743 | 1198 | 869 | 332 |
Cash Interest Paid | 194 | 721 | 522 | 323 | 187 |
Changes in Working Capital | 1382 | -443 | 343 | -335 | 691 |
Cash From Investing Activities | -168 | -11058 | -10145 | 319 | 555 |
Capital Expenditures | -363 | -2200 | -1482 | -822 | -469 |
Other Investing Cash Flow Items, Total | 195 | -8858 | -8663 | 1141 | 1024 |
Cash From Financing Activities | -3740 | 3649 | 4700 | 4558 | -2731 |
Financing Cash Flow Items | -997 | -178 | -28 | -22 | -23 |
Total Cash Dividends Paid | -2971 | -3856 | -3856 | -2469 | -2469 |
Issuance (Retirement) of Stock, Net | 5 | 29 | 10 | 9 | 5 |
Issuance (Retirement) of Debt, Net | 223 | 7654 | 8574 | 7040 | -244 |
Foreign Exchange Effects | -9 | -62 | -73 | -52 | -67 |
Net Change in Cash | -685 | -1508 | -973 | 7651 | -309 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.5099 | 100893184 | 1200 | 2023-01-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 4.2 | 65092368 | 768 | 2023-01-31 | LOW |
Capital Research Global Investors | Investment Advisor | 4.12 | 63852512 | 752 | 2023-01-31 | LOW |
Investor AB | Private Equity | 3.33 | 51608948 | 608 | 2023-01-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.8464 | 44114976 | -1215991 | 2022-12-14 | LOW |
Capital World Investors | Investment Advisor | 1.7648 | 27351981 | 2675871 | 2022-12-14 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.1934 | 18495433 | 289630 | 2023-03-01 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.1402 | 17670785 | 0 | 2023-03-01 | LOW |
GQG Partners, LLC | Investment Advisor | 1.0697 | 16579162 | 1036509 | 2022-12-14 | MED |
State Street Global Advisors (UK) Ltd. | Investment Advisor/Hedge Fund | 0.6303 | 9768142 | 18173 | 2023-03-01 | LOW |
Nuveen LLC | Pension Fund | 0.6158 | 9543355 | 495683 | 2022-12-14 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5411 | 8386244 | -95567 | 2022-12-14 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.5082 | 7875720 | 214842 | 2022-12-14 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.5022 | 7783223 | -7029 | 2023-03-01 | LOW |
Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.5003 | 7754095 | 612331 | 2023-03-01 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 0.4726 | 7325050 | 98350 | 2023-03-01 | LOW |
Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 0.4702 | 7287300 | 922173 | 2023-02-28 | LOW |
Union Investment Privatfonds GmbH | Investment Advisor | 0.3731 | 5782579 | -203480 | 2022-12-31 | LOW |
Royal London Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.3705 | 5741791 | 5792 | 2023-03-01 | LOW |
Schroder Investment Management Ltd. (SIM) | Investment Advisor/Hedge Fund | 0.3701 | 5735207 | 34985 | 2023-03-01 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AstraZeneca - GBP Company profile
Ettevõttest AstraZeneca PLC - GBP
AstraZeneca PLC (AstraZeneca) on patsiendile keskendunud biofarmatseutiline ettevõte. Ettevõte keskendub retseptiravimite avastamisele ja arendamisele, tootmisele ja turustamisele, peamiselt haiguste raviks. Ettevõte keskendub kolmele peamisele ravivaldkonnale: Onkoloogia; kardiovaskulaarne, neeru- ja ainevahetus ning hingamisteede ja immunoloogia. Ettevõtte tooteprogramm moodustab tugeva portfelli uuritavaid ravimeid, mis on kliinilise arengu erinevates etappides. Ettevõttel on juurdepääs tehnoloogiatele nii ettevõttesiseselt kui ka erinevate koostööpartnerite kaudu. Ettevõtte tehnoloogiate hulka kuuluvad akustiline torutehnoloogia, täiustatud molekulaarkujundus, krüoelektronmikroskoopia (krüo-EM), funktsionaalne genoomika, multi-oomika ja AstraZeneca iLab. Ettevõtte akustilise toru tehnoloogia aitab tal käsitleda ja töödelda miljoneid ühendeid bioloogiliseks sõelumiseks. AstraZeneca iLab on tema automatiseeritud meditsiinikeemia laboratooriumi prototüüp.
Industry: | Pharmaceuticals (NEC) |
1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com